C12Y 201/01045
Thymidylate synthase
Official title: Thymidylate synthase (2.1.1.45)
C12Y201/01045 (Thymidylate synthase) appears on 13 US grants and 35 published applications in this corpus.
Search patents in C12Y- Granted patents
- 13
- Published applications
- 35
- Assignees
- 22
- Inventors
- 89
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 2 | 2 |
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 0 | 2 |
| 2009 | 0 | 0 |
| 2010 | 1 | 2 |
| 2011 | 0 | 2 |
| 2012 | 1 | 1 |
| 2013 | 1 | 0 |
| 2014 | 0 | 2 |
| 2015 | 0 | 1 |
| 2016 | 1 | 0 |
| 2017 | 2 | 1 |
| 2018 | 0 | 3 |
| 2019 | 0 | 2 |
| 2020 | 1 | 3 |
| 2021 | 1 | 4 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 0 | 4 |
| 2025 | 0 | 1 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods of treatment comprising tumor-targeting bacteria and chemotherapy or immunotherapy agent9 Jun 2026US 12,648,970 B2The Curators of the University of Missouri
- Methods of treating cancer by inhibition of DNA repair proteins using antisense based therapies2 Feb 2021US 10,907,159 B2Sarissa Inc.
- Selection methods for genetically-modified T cells20 Oct 2020US 10,808,230 B2Board of Regents, The University of Texas System
- SRM assay to indicate cancer therapy12 Dec 2017US 9,840,728 B2Expression Pathology, Inc.
- Escherichia coli cell line with thyA knockout and folA knockout4 Apr 2017US 9,611,503 B2National Science and Technology Development Agency
- Compositions and Methods for Cancer Immunotherapy9 Oct 2025US 2025/0313803 A1IN8bio, Inc.
- Fibroblast delivery of tumor inhibitory agents5 Sep 2024US 2024/0293468 A1Figene, LLC
- Fibroblast delivery of tumor inhibitory agents5 Sep 2024US 2024/0293469 A1Figene, LLC
- Auxotrophic Cells for Virus Production and Compositions and Methods of Making18 Apr 2024US 2024/0124850 A1Shape Therapeutics Inc.
- Compositions and methods of treatment comprising tumor-targeting bacteria and chemotherapy or immunotherapy agent11 Jan 2024US 2024/0009252 A1Cancer Research Center
Most cited
By later US patents
- Microorganism strain CRC2631 of Salmonella typhimurium and its use as a cancer therapeutic16US 8,282,919 B2Cancer Research Center · 2012
- Genetic system and self-cleaving inteins derived therefrom, bioseparations and protein purification employing same, and methods for determining critical, generalizable amino acid residues for varying intein activity15US 6,933,362 B1Rensselaer Polytechnic Institute · 2005
- Self-containing Lactococcus strain9US 7,780,961 B2ActoGeniX N V · 2010
- Antisense oligonucleotide modulation of human thymidylate synthase expression6US 6,087,489 AIsis Pharmaceuticals, Inc. · 2000
- Mutants of thymidylate synthase and uses thereof5US 6,416,987 B1Sloan-Kettering Institute for Cancer Research · 2002